BR112019020373A2 - micropartículas revestidas com minerais para liberação sustentada de moléculas biologicamente ativas - Google Patents

micropartículas revestidas com minerais para liberação sustentada de moléculas biologicamente ativas Download PDF

Info

Publication number
BR112019020373A2
BR112019020373A2 BR112019020373-7A BR112019020373A BR112019020373A2 BR 112019020373 A2 BR112019020373 A2 BR 112019020373A2 BR 112019020373 A BR112019020373 A BR 112019020373A BR 112019020373 A2 BR112019020373 A2 BR 112019020373A2
Authority
BR
Brazil
Prior art keywords
mineral
active agent
antagonist
fact
coating
Prior art date
Application number
BR112019020373-7A
Other languages
English (en)
Portuguese (pt)
Inventor
Murphy William
Clements Anna
Chamberlain Connie
Vanderby Ray
Original Assignee
Wisconsin Alumni Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Research Foundation filed Critical Wisconsin Alumni Research Foundation
Publication of BR112019020373A2 publication Critical patent/BR112019020373A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Ceramic Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112019020373-7A 2017-04-03 2018-04-03 micropartículas revestidas com minerais para liberação sustentada de moléculas biologicamente ativas BR112019020373A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762480710P 2017-04-03 2017-04-03
US62/480,710 2017-04-03
PCT/US2018/025913 WO2018187344A1 (en) 2017-04-03 2018-04-03 Mineral coated microparticles for sustained delivery of biologically active molecules

Publications (1)

Publication Number Publication Date
BR112019020373A2 true BR112019020373A2 (pt) 2020-04-28

Family

ID=63712804

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019020373-7A BR112019020373A2 (pt) 2017-04-03 2018-04-03 micropartículas revestidas com minerais para liberação sustentada de moléculas biologicamente ativas

Country Status (10)

Country Link
US (1) US12465654B2 (enExample)
EP (1) EP3606512A4 (enExample)
JP (1) JP7170031B2 (enExample)
KR (1) KR20190130643A (enExample)
CN (1) CN110691588A (enExample)
AU (1) AU2018249816B2 (enExample)
BR (1) BR112019020373A2 (enExample)
CA (1) CA3058802A1 (enExample)
IL (1) IL269607A (enExample)
WO (1) WO2018187344A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019020373A2 (pt) 2017-04-03 2020-04-28 Wisconsin Alumni Research Foundation micropartículas revestidas com minerais para liberação sustentada de moléculas biologicamente ativas
WO2022051247A1 (en) * 2020-09-01 2022-03-10 Dianomi Therapeutics, Inc. Methods for treating or preventing inflammatory events
DE102020129648A1 (de) * 2020-11-10 2022-05-12 Leopold MTX GmbH Pharmazeutische zusammensetzung
CN114917364A (zh) * 2022-05-12 2022-08-19 云南大学附属医院 一种携IL-8和Anakinra双配体靶向纳米微泡的制备方法
WO2024102801A2 (en) * 2022-11-09 2024-05-16 Wisconsin Alumni Research Foundation Mineral-coated iron oxide microparticles and use of same including use for immunomodulation

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
TWI267378B (en) * 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
JP2003212756A (ja) * 2002-01-21 2003-07-30 Olympus Optical Co Ltd 薬剤徐放剤
JP5022216B2 (ja) * 2004-06-04 2012-09-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 自己炎症性疾患を処置するためのｉｌ−１アンタゴニストを使用する方法
US7655758B2 (en) * 2004-08-17 2010-02-02 Regeneron Pharmaceuticals, Inc. Stable liquid IL-1 antagonist formulations
US7473678B2 (en) * 2004-10-14 2009-01-06 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods of use thereof
WO2007033372A2 (en) * 2005-09-14 2007-03-22 Mannkind Corporation Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
JPWO2008041704A1 (ja) * 2006-10-02 2010-02-04 独立行政法人物質・材料研究機構 徐放性製剤
US20100143439A1 (en) * 2007-04-16 2010-06-10 University Of Toledo Hybrid Biomimetic Particles, Methods of Making Same and Uses Therefor
US8470360B2 (en) 2008-04-18 2013-06-25 Warsaw Orthopedic, Inc. Drug depots having different release profiles for reducing, preventing or treating pain and inflammation
US20090111763A1 (en) * 2007-10-26 2009-04-30 Celonova Biosciences, Inc. Loadable polymeric particles for bone augmentation and methods of preparing and using the same
CN102014975A (zh) 2008-02-29 2011-04-13 史密夫和内修有限公司 用于生物医学应用的梯度涂层
US20100015049A1 (en) * 2008-07-16 2010-01-21 Warsaw Orthopedic, Inc. Methods and compositions for treating postoperative pain comprising nonsteroidal anti-inflammatory agents
EP2349212B1 (en) * 2008-09-25 2022-01-19 TRS Holdings LLC Mineral-coated microspheres
US20160017368A1 (en) * 2013-02-19 2016-01-21 Wisconsin Alumni Research Foundation Inorganic coatings for the enhancement of chemical transfection
JP6827960B2 (ja) 2015-03-03 2021-02-10 ティーアールエス ホールディングス リミテッド ライアビリティ カンパニー コーティングスキャフォールド
EP4026568A1 (en) 2015-04-17 2022-07-13 CureVac Real Estate GmbH Lyophilization of rna
BR112019020373A2 (pt) 2017-04-03 2020-04-28 Wisconsin Alumni Research Foundation micropartículas revestidas com minerais para liberação sustentada de moléculas biologicamente ativas
EP3648750A4 (en) 2017-07-05 2021-05-26 Wisconsin Alumni Research Foundation MINERAL-COATED MICROPARTICLE FOR THE SIMULTANEOUS ADMINISTRATION OF ANTI-INFLAMMATORY MOLECULES WITH NUCLEIC ACIDS TO IMPROVE THE GENERAL TRANSFER RESULTS
WO2019010304A1 (en) 2017-07-05 2019-01-10 Wisconsin Alumni Research Foundation MICROPARTICLES COATED WITH MINERALS FOR GENES ADMINISTRATION IN CHRONIC WOUND THERAPY
EP3556728A1 (en) 2018-04-16 2019-10-23 Croda Denmark A/S Organically modified mineral micro-particles, methods of preparing the same and uses thereof
US20190358344A1 (en) 2018-05-23 2019-11-28 Dianomi Therapeutics, Inc. Mineral coated microparticles for sustained delivery of steroids
US20240325596A1 (en) 2021-11-09 2024-10-03 Wisconsin Alumni Research Foundation Mineral-coated substrates for stabilization of rna-based therapeutic compositions

Also Published As

Publication number Publication date
IL269607A (en) 2019-11-28
EP3606512A4 (en) 2021-01-13
EP3606512A1 (en) 2020-02-12
KR20190130643A (ko) 2019-11-22
CA3058802A1 (en) 2018-10-11
AU2018249816B2 (en) 2025-04-17
US20200164087A1 (en) 2020-05-28
JP2020513033A (ja) 2020-04-30
CN110691588A (zh) 2020-01-14
US12465654B2 (en) 2025-11-11
AU2018249816A1 (en) 2019-10-17
JP7170031B2 (ja) 2022-11-11
WO2018187344A1 (en) 2018-10-11

Similar Documents

Publication Publication Date Title
Qiao et al. TRPM7 kinase-mediated immunomodulation in macrophage plays a central role in magnesium ion-induced bone regeneration
Gao et al. Hydrogel–metal-organic-framework hybrids mediated efficient oral delivery of siRNA for the treatment of ulcerative colitis
BR112019020373A2 (pt) micropartículas revestidas com minerais para liberação sustentada de moléculas biologicamente ativas
Ma et al. Enhanced osteolysis targeted therapy through fusion of exosomes derived from M2 macrophages and bone marrow mesenchymal stem cells: modulating macrophage polarization
Ummarino et al. Therapeutic manipulation of macrophages using nanotechnological approaches for the treatment of osteoarthritis
CN108348646A (zh) 用于预防或治疗软组织疾病的多孔聚合物微球及其制造方法
Xie et al. Targeted therapy for peri-prosthetic osteolysis using macrophage membrane-encapsulated human urine-derived stem cell extracellular vesicles
Yang et al. Mannose-mediated nanodelivery of methotrexate to macrophages augments rheumatoid arthritis therapy
He et al. High-density lipoprotein nanoparticles spontaneously target to damaged renal tubules and alleviate renal fibrosis by remodeling the fibrotic niches
Schweizer et al. Pharmacokinetics, biocompatibility and bioavailability of a controlled release monoclonal antibody formulation
Huang et al. Articular Cartilage Regeneration via Induced Chondrocyte Autophagy by Sustained Release of Leptin Inhibitor from Thermo‐Sensitive Hydrogel through STAT3/REDD1/mTORC1 Cascade
Li et al. Synergistic metabolic modulation of fibroblast-like synoviocytes via targeted dual prodrug nanoparticles to mitigate rheumatoid arthritis
Wang et al. Recent advances in polymeric microparticle-based drug delivery systems for knee osteoarthritis treatment
Lu et al. Trojan horse-inspired spatiotemporal strategy augments cartilage regeneration by enhancing mitochondrial energy production
CA3223710A1 (en) Pharmaceutical compositions comprising glp-1r agonists
He et al. Enhanced anti-rheumatic efficacy of PLGA-based methotrexate-loaded implants in adjuvant-induced arthritis rat model
Parveen et al. An Outlook of Substantial Progress in Nanotechnology Emerged in Treatment Approaches for Rheumatoid Arthritis
Ubhe IL-1 receptor antagonist: etiological and drug delivery systems overview
WO2022051247A1 (en) Methods for treating or preventing inflammatory events
Tao et al. Research of brain targeting nano-metformin on cerebral ischemia-reperfusion injury based on microglial cell activation
Mohaghegh et al. Immunoengineering strategies using nanoparticles for obesity treatment
HK40014557A (en) Mineral coated microparticles for sustained delivery of biologically active molecules
Zhang et al. A size-switchable microsphere loaded with salmon calcitonin as two-weekly dosing for osteoporosis therapy
JP2024502825A (ja) 抗体の局所的延長放出
Zamudio-Cuevas et al. Emergent nanotherapies in microcrystal-induced arthritis

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]